Tegavivint
Tegavivint is a pharmaceutical drug with 8 clinical trials. Currently 7 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
8
Early Stage
0
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 1Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
7
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Tegavivint for the Treatment of Relapsed or Refractory Leukemia
Clinical Trials (8)
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Tegavivint for the Treatment of Relapsed or Refractory Leukemia
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8